Chronic kidney disease and fibrosis: The role of uremic retention solutes

Frontiers in Medicine

Volumn 2, Issue AUG, 2015, Pages

  Mutsaers, Henricus A M ^a   Stribos, Elisabeth G D ^a,b   Glorieux, Griet ^c   Vanholder, Raymond ^c   Olinga, Peter ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cardiac fibrosis; Chronic kidney disease; Epithelial to mesenchymal transition; Renal fibrosis; TGF ; Uremic retention solutes

Indexed keywords

EID: 84977972595     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00060     Document Type: Short Survey

References (81)

1. Meyer TW, Hostetter TH. Uremia. N Engl J Med (2007) 357(13):1316-25. doi: 10.1056/NEJMra071313
2. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int (2006) 69(2):213-7. doi:10.1038/sj.ki.5000054
3. Rockey DC, Bell PD, Hill JA. Fibrosis-a common pathway to organ injury and failure. N Engl J Med (2015) 372(12):1138-49. doi:10.1056/NEJMra1300575
4. Lee SY, Kim SI, Choi ME. Therapeutic targets for treating fibrotic kidney diseases. Transl Res (2015) 165(4):512-30. doi:10.1016/j.trsl.2014.07.010
5. Schanstra JP, Zurbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrol (2015) 26(8):1999-2010. doi:10.1681/ASN.2014050423
6. Yamazaki KG, Gonzalez E, Zambon AC. Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: role of the cardiac fibroblast. J Cardiovasc Transl Res (2012) 5(6):805-13. doi:10.1007/s12265-012-9405-4
7. Gonzalez A, Lopez B, Diez J. Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. Med Clin North Am (2004) 88(1):83-97. doi:10.1016/S0025-7125(03)00125-1
8. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J (2010) 31(14):1771-9. doi:10.1093/eurheartj/ehp574
9. Yisireyili M, Shimizu H, Saito S, Enomoto A, Nishijima F, Niwa T. Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci (2013) 92(24-26):1180-5. doi:10.1016/j.lfs.2013.05.008
10. Ronco C, Di Lullo L. Cardiorenal syndrome. Heart Fail Clin (2014) 10(2):251-80. doi:10.1016/j.hfc.2013.12.003
11. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res (2012) 111(11):1470-83. doi:10.1161/CIRCRESAHA.112.278457
12. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant (2005) 20(6):1048-56. doi:10.1093/ndt/gfh813
13. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (2010) 375(9731):2073-81. doi:10.1016/S0140-6736(10)60674-5
14. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant (2006) 21(9):2549-55. doi:10.1093/ndt/gfl271
15. Verbeke F, Van Biesen W, Vanholder R. The role of collagen metabolism in CKD-associated arterial senescence: underestimated and underappreciated. Nephrol Dial Transplant (2011) 26(9):2726-8. doi:10.1093/ndt/gfr421
16. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 121(4):505-11. doi:10.1161/CIRCULATIONAHA.109.886655
17. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol (2010) 21(8):1247-53. doi:10.1681/ASN.2010060616
18. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol (2010) 21(2):212-22. doi:10.1681/ASN.2008121226
19. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest (2011) 121(2):468-74. doi:10.1172/JCI44595
20. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest (2014) 124(6):2299-306. doi:10.1172/JCI72267
21. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest (2003) 112(12):1776-84. doi:10.1172/JCI200320530
22. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol (2014) 25(9):1897-907. doi:10.1681/ASN.2013101062
23. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol (2012) 13(10):616-30. doi:10.1038/nrm3434
24. Fine LG, Hammerman MR, Abboud HE. Evolving role of growth factors in the renal response to acute and chronic disease. J Am Soc Nephrol (1992) 2(7):1163-70
25. Kaneto H, Morrissey J, Klahr S. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int (1993) 44(2):313-21. doi:10.1038/ki.1993.246
26. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest (1996) 74(6):991-1003
27. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Lariviere R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens (2005) 23(10):1895-903. doi:10.1097/01.hjh.0000182521.44440.c5
28. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int (2003) 63(5):1671-80. doi:10.1046/j.1523-1755.2003.00906.x
29. Zhao YY, Cheng XL, Wei F, Bai X, Tan XJ, Lin RC, et al. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-beta1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MS(E). J Proteome Res (2013) 12(2):692-703. doi:10.1021/pr3007792
30. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol (2009) 4(10):1551-8. doi:10.2215/CJN.03980609
31. Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant (2008) 23(6):1892-901. doi:10.1093/ndt/gfm861
32. Chiu CA, Lu LF, Yu TH, Hung WC, Chung FM, Tsai IT, et al. Increased levels of total P-cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud (2010) 7(4):275-84. doi:10.1900/RDS.2010.7.275
33. Miyazaki T, Ise M, Seo H, Niwa T. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl (1997) 62:S15-22
34. Miyazaki T, Ise M, Hirata M, Endo K, Ito Y, Seo H, et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl (1997) 63:S211-4
35. Kutz SM, Hordines J, McKeown-Longo PJ, Higgins PJ. TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci (2001) 114(Pt 21):3905-14
36. Pham BT, van Haaften WT, Oosterhuis D, Nieken J, de Graaf IA, Olinga P. Precision-cut rat, mouse, and human intestinal slices as novel models for the early-onset of intestinal fibrosis. Physiol Rep (2015) 3(4):e12323. doi:10.14814/phy2.12323
37. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol (2006) 17(11):2999-3012. doi:10.1681/ASN.2006050503
38. Saito S, Shimizu H, Yisireyili M, Nishijima F, Enomoto A, Niwa T. Indoxyl sulfate-induced activation of (pro)renin receptor is involved in expression of TGF-beta1 and alpha-smooth muscle actin in proximal tubular cells. Endocrinology (2014) 155(5):1899-907. doi:10.1210/en.2013-1937
39. Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One (2012) 7(3):e34026. doi:10.1371/journal.pone.0034026
40. Galichon P, Finianos S, Hertig A. EMT-MET in renal disease: should we curb our enthusiasm? Cancer Lett (2013) 341(1):24-9. doi:10.1016/j.canlet.2013.04.018
41. Xu-Dubois YC, Baugey E, Peltier J, Colombat M, Ouali N, Jouanneau C, et al. Epithelial phenotypic changes are associated with a tubular active fibrogenic process in human renal grafts. Hum Pathol (2013) 44(7):1251-61. doi:10.1016/j.humpath.2012.10.010
42. Bolati D, Shimizu H, Higashiyama Y, Nishijima F, Niwa T. Indoxyl sulfate induces epithelial-to-mesenchymal transition in rat kidneys and human proximal tubular cells. Am J Nephrol (2011) 34(4):318-23. doi:10.1159/000330852
43. Kim SH, Yu MA, Ryu ES, Jang YH, Kang DH. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest (2012) 92(4):488-98. doi:10.1038/labinvest.2011.194
44. Mutsaers HA, Engelke UF, Wilmer MJ, Wetzels JF, Wevers RA, van den Heuvel LP, et al. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients. PLoS One (2013) 8(8):e71199. doi:10.1371/journal.pone.0071199
45. Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol (2015) 11(5):264-76. doi:10.1038/nrneph.2015.3
46. Shimizu H, Bolati D, Adijiang A, Enomoto A, Nishijima F, Dateki M, et al. Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am J Physiol Cell Physiol (2010) 299(5):C1110-7. doi:10.1152/ajpcell.00217.2010
47. Shimizu H, Yisireyili M, Nishijima F, Niwa T. Stat3 contributes to indoxyl sulfate-induced inflammatory and fibrotic gene expression and cellular senescence. Am J Nephrol (2012) 36(2):184-9. doi:10.1159/000341515
48. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature (1997) 390(6655):45-51. doi:10.1038/36285
49. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol (2013) 75:503-33. doi:10.1146/annurev-physiol-030212-183727
50. Mutsaers HA, Levtchenko EN, Martinerie L, Pertijs JC, Allegaert K, Devriendt K, et al. Switch in FGFR3 and-4 expression profile during human renal development may account for transient hypercalcemia in patients with Sotos syndrome due to 5q35 microdeletions. J Clin Endocrinol Metab (2014) 99(7):E1361-7. doi:10.1210/jc.2014-1123
51. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem (2011) 286(10):8655-65. doi:10.1074/jbc.M110.174037
52. Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol (2013) 180:47-63. doi:10.1159/000346778
53. Adijiang A, Shimizu H, Higuchi Y, Nishijima F, Niwa T. Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats. J Ren Nutr (2011) 21(1):105-9. doi:10.1053/j.jrn.2010.10.020
54. Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int (2012) 81(7):640-50. doi:10.1038/ki.2011.445
55. de Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem (2005) 51(8):1535-8. doi:10.1373/clinchem.2005.050781
56. Mutsaers HAM, Caetano-Pinto P, Seegers AEM, Dankers ACA, van den Broek PHH, Wetzels JFM, et al. Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: implications for chronic kidney disease pathophysiology. Toxicol In Vitro (2015) 29(7):1868-77. doi:10.1016/j.tiv.2015.07.020
57. Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int (2013) 83(4):582-92. doi:10.1038/ki.2012.448
58. Mutsaers HA, van den Heuvel LP, Ringens LH, Dankers AC, Russel FG, Wetzels JF, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One (2011) 6(4):e18438. doi:10.1371/journal.pone.0018438
59. Mutsaers HA, Wilmer MJ, Reijnders D, Jansen J, van den Broek PH, Forkink M, et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta (2013) 1832(1):142-50. doi:10.1016/j.bbadis.2012.09.006
60. Satoh M, Hayashi H, Watanabe M, Ueda K, Yamato H, Yoshioka T, et al. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol (2003) 95(3):e111-8. doi:10.1159/000074327
61. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372(6505):425-32. doi:10.1038/372425a0
62. Meyer C, Robson D, Rackovsky N, Nadkarni V, Gerich J. Role of the kidney in human leptin metabolism. Am J Physiol (1997) 273(5 Pt 1):E903-7
63. Shankar A, Syamala S, Xiao J, Muntner P. Relationship between plasma leptin level and chronic kidney disease. Int J Nephrol (2012) 2012:269532. doi:10.1155/2012/269532
64. Sharma K, Considine RV, Michael B, Dunn SR, Weisberg LS, Kurnik BR, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int (1997) 51(6):1980-5. doi:10.1038/ki.1997.269
65. Alix PM, Guebre-Egziabher F, Soulage CO. Leptin as an uremic toxin: deleterious role of leptin in chronic kidney disease. Biochimie (2014) 105:12-21. doi:10.1016/j.biochi.2014.06.024
66. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [see comments]. Kidney Int (1999) 56(3):860-72. doi:10.1046/j.1523-1755.1999.00626.x
67. Briffa JF, Grinfeld E, Mathai ML, Poronnik P, McAinch AJ, Hryciw DH. Acute leptin exposure reduces megalin expression and upregulates TGFbeta1 in cultured renal proximal tubule cells. Mol Cell Endocrinol (2015) 401:25-34. doi:10.1016/j.mce.2014.11.024
68. Lee CI, Guh JY, Chen HC, Lin KH, Yang YL, Hung WC, et al. Leptin and connective tissue growth factor in advanced glycation end-product-induced effects in NRK-49F cells. J Cell Biochem (2004) 93(5):940-50. doi:10.1002/jcb.20222
69. Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM, et al. Leptin mediates the increase in blood pressure associated with obesity. Cell (2014) 159(6):1404-16. doi:10.1016/j.cell.2014.10.058
70. Allison MA, Ix JH, Morgan C, McClelland RL, Rifkin D, Shimbo D, et al. Higher leptin is associated with hypertension: the Multi-Ethnic Study of Atherosclerosis. J Hum Hypertens (2013) 27(10):617-22. doi:10.1038/jhh.2013.24
71. Schepers E, Speer T, Bode-Boger SM, Fliser D, Kielstein JT. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins? Semin Nephrol (2014) 34(2):97-105. doi:10.1016/j.semnephrol.2014.02.003
72. Mallipattu SK, He JC, Uribarri J. Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients. Semin Dial (2012) 25(5):529-38. doi:10.1111/j.1525-139X.2012.01081.x
73. Bagrov AY, Shapiro JI, Fedorova OV. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev (2009) 61(1):9-38. doi:10.1124/pr.108.000711
74. Gonick HC, Ding Y, Vaziri ND, Bagrov AY, Fedorova OV. Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens (1998) 20(5-6):617-27. doi:10.3109/10641969809053240
75. Komiyama Y, Dong XH, Nishimura N, Masaki H, Yoshika M, Masuda M, et al. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem (2005) 38(1):36-45. doi:10.1016/j.clinbiochem.2004.08.005
76. Fedorova LV, Raju V, El-Okdi N, Shidyak A, Kennedy DJ, Vetteth S, et al. The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition. Am J Physiol Renal Physiol (2009) 296(4):F922-34. doi:10.1152/ajprenal.90605.2008
77. Haller ST, Drummond CA, Yan Y, Liu J, Tian J, Malhotra D, et al. Passive immunization against marinobufagenin attenuates renal fibrosis and improves renal function in experimental renal disease. Am J Hypertens (2014) 27(4):603-9. doi:10.1093/ajh/hpt169
78. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One (2012) 7(7):e41281. doi:10.1371/journal.pone.0041281
79. Bolati D, Shimizu H, Niwa T. AST-120 ameliorates epithelial-to-mesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats. J Ren Nutr (2012) 22(1):176-80. doi:10.1053/j.jrn.2011.10.015
80. Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl (2009) 114:S12-9. doi:10.1038/ki.2009.402
81. Masereeuw R, Mutsaers HA, Toyohara T, Abe T, Jhawar S, Sweet DH, et al. The kidney and uremic toxin removal: glomerulus or tubule? Semin Nephrol (2014) 34(2):191-208. doi:10.1016/j.semnephrol.2014.02.010